Folic acid (Synonyms: Vitamin B9; Vitamin M)

Name: Folic acid
Brand: MedChemExpress
SKU: HY-16637
Rating: 5.0 (25 reviews)

Cat. No.: HY-16637 Purity: 99.02%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Folic acid (Vitamin B9) is a orally active essential nutrient from the B complex group of vitamins. Folic acid shows antidepressant-like effect. Folic acid sodium reduces the risk of neonatal neural tube defects. Folic acid can be used to the research of megaloblastic and macrocytic anemias due to folic deficiency.

For research use only. We do not sell to patients.

CAS No. : 59-30-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
25 g	In-stock	Estimated Time of Arrival: December 31
50 g	In-stock	Estimated Time of Arrival: December 31
100 g	In-stock	Estimated Time of Arrival: December 31
> 100 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 25 publication(s) in Google Scholar

Other Forms of Folic acid:

25 Publications Citing Use of MCE Folic acid

RT-PCR

Histological Imaging/Staining

IHC

: Folic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Dec 8:S2090-1232(25)00996-8. [Abstract]; Epithelial junctional proteins were upregulated by Folic acid (30 mg/kg) treated.

: Folic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Dec 8:S2090-1232(25)00996-8. [Abstract]; Decreased expression of mesenchymal markers, MMPs, and EMT regulators after Folic acid (30 mg/kg) administration.

: Folic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Dec 8:S2090-1232(25)00996-8. [Abstract]; Folic acid (30 mg/kg) restored epithelial architecture, as evidenced by the increase in crypt integrity, maintenance of goblet cells.

: Folic acid purchased from MedChemExpress. Usage Cited in: JCI Insight. 2022 Apr 8;7(7):e152330. [Abstract]; mRNA levels of TGF-β1, α-SMA, and fibronectin in the kidney of CTL, Folic acid (FAN) (250 mg/kg, IP, 7 days), and FAN+GsMTx4 mice.

: Folic acid purchased from MedChemExpress. Usage Cited in: JCI Insight. 2022 Apr 8;7(7):e152330. [Abstract]; Photomicrographs of Masson’s staining in the kidney of CTL, Folic acid (FAN) (250 mg/kg, IP, 7 days), and FAN+GsMTx4 mice.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms

RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

Microbial Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
K562	IC₅₀	290 μM Compound: folate	Ability to inhibit thymidylate synthase derived from human leukemia K562 cells Ability to inhibit thymidylate synthase derived from human leukemia K562 cells	[PMID: 3470522]
KB	IC₅₀	0.5 μM Compound: folic acid	Photocytotoxicity against human KB cells overexpressing folate receptor assessed as cell viability incubated for 24 hrs followed by halogen light illumination measured after 20 mins by MTT assay Photocytotoxicity against human KB cells overexpressing folate receptor assessed as cell viability incubated for 24 hrs followed by halogen light illumination measured after 20 mins by MTT assay	[PMID: 24088087]
L1210	IC₅₀	0.00018 M Compound: table II	Inhibitory activity against the thymidylate synthase in the Permeabilized L1210 cells Inhibitory activity against the thymidylate synthase in the Permeabilized L1210 cells	[PMID: 3100797]
L1210	IC₅₀	> 0.001 M Compound: table II	Inhibitory activity against thymidylate synthase in the intact L1210 cells Inhibitory activity against thymidylate synthase in the intact L1210 cells	[PMID: 3100797]
L1210	IC₅₀	> 10 mM Compound: Folic acid	Inhibitory activity against growth of L1210 leukemia cells in culture Inhibitory activity against growth of L1210 leukemia cells in culture	[PMID: 1560436]
MOLT-4	IC₅₀	> 100 μM Compound: Folic acid	Compound was evaluated for inhibition of MTX influx into MOLT-4 cells Compound was evaluated for inhibition of MTX influx into MOLT-4 cells	[PMID: 1895294]

In Vitro

Folic acid plays a critical role in the prevention of chromosome breakage and hypomethylation of DNA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Folic acid can be used to induce acute kidney injury models. In rats, oral administration results in an AUC of 1.4 μg h/mL, with an oral bioavailability of 35%^[5].

Induction of Acute Kidney Injury (AKI)^[6]

Background

Folic acid metabolism requires higher levels of NADPH to reduce folate to THF decreasing the antioxidant defense. The redox imbalance generated by folic acid metabolism is one of the main mechanisms involved in renal damage.

Specific Modeling Methods

Rat: Wistar • male
Administration: 300mg/ml • i.p. • single dose

Note

(1) Intraperitoneal injection 300 mg/kg folic acid (dissolved in 300 mM NaHCO) in male Wistar rats with an initial body weight between 230 to 250 g.
(2) Plasma was collected and analyzed at days 2, 4, 7, 14 and 28 after folic acid administration.

Modeling Indicators

Metabolic changes : Assessment of renal injury by blood urea nitrogen (BUN) and plasma creatinine.
Individual phenotypic change: The ratio of kidney weight to total rat weight was detected.

Correlated Product(s): Acetylcysteine (HY-B0215)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	30-40 g swiss mice^[2]
Dosage:	10, 50, 100 mg/kg
Administration:	Oral administration
Result:	Decreased the immobility time in the forced swimming test (FST) (F₃₂₄=11.21) and produced a significant effect in the immobility time in the tail suspension test (TST) (F_3,20=5.71).

Animal Model:	30-40 g swiss mice^[2]
Dosage:	1-10 nmol/site
Administration:	Intracerebroventrical injection
Result:	Decreased the immobility time of mice in the FST (F_3,22=12.31) and TST (F_3,22=5.50).

Animal Model:	Virgin female Wistar rats^[3]
Dosage:	1, 5 mg/kg (180 g/kg protein with 1 mg/kg folic acid or 90 g/kg casein with 1, 5 mg/kg folic acid)
Administration:	Oral administration
Result:	Prevented epigenetic modification of hepatic gene expression in the offspring.

Clinical Trial

Molecular Weight

441.40

Formula

C₁₉H₁₉N₇O₆

CAS No.

59-30-3

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(O)CC[C@@H](C(O)=O)NC(C1=CC=C(NCC2=CN=C3N=C(N)NC(C3=N2)=O)C=C1)=O

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Microorganisms

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

RT, protect from light

In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

1M NaOH : 100 mg/mL (226.55 mM; Need ultrasonic)

DMSO : 33.33 mg/mL (75.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2655 mL	11.3276 mL	22.6552 mL
5 mM	0.4531 mL	2.2655 mL	4.5310 mL
10 mM	0.2266 mL	1.1328 mL	2.2655 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 300 mM Sodium bicarbonate in Water
Solubility: 50 mg/mL (113.28 mM); Clear solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.71 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.40%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (245 KB) HNMR (132 KB) RP-HPLC (180 KB)

Handling Instructions (2659 KB)

References

[1]. Butterworth CE Jr, et al. Folic acid safety and toxicity: a brief review. Am J Clin Nutr. 1989 Aug;50(2):353-8. [Content Brief]

[2]. Brocardo PS, et al. Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology. 2008 Feb;54(2):464-73. [Content Brief]

[3]. Lillycrop KA, et al. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr. 2005 Jun;135(6):1382-6. [Content Brief]

[4]. Pietrzik K, et al. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010 Aug;49(8):535-48. [Content Brief]

[5]. Peñalva R, et al. Zein nanoparticles for oral folic acid delivery[J]. Journal of Drug Delivery Science and Technology, 2015, 30: 450-457.

[6]. Aparicio-Trejo OE, et al. Chronic impairment of mitochondrial bioenergetics and β-oxidation promotes experimental AKI-to-CKD transition induced by folic acid. Free Radic Biol Med. 2020 Jul;154:18-32. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / 1M NaOH	1 mM	2.2655 mL	11.3276 mL	22.6552 mL	56.6380 mL
	5 mM	0.4531 mL	2.2655 mL	4.5310 mL	11.3276 mL
	10 mM	0.2266 mL	1.1328 mL	2.2655 mL	5.6638 mL
	15 mM	0.1510 mL	0.7552 mL	1.5103 mL	3.7759 mL
	20 mM	0.1133 mL	0.5664 mL	1.1328 mL	2.8319 mL
	25 mM	0.0906 mL	0.4531 mL	0.9062 mL	2.2655 mL
	30 mM	0.0755 mL	0.3776 mL	0.7552 mL	1.8879 mL
	40 mM	0.0566 mL	0.2832 mL	0.5664 mL	1.4159 mL
	50 mM	0.0453 mL	0.2266 mL	0.4531 mL	1.1328 mL
	60 mM	0.0378 mL	0.1888 mL	0.3776 mL	0.9440 mL
1M NaOH	80 mM	0.0283 mL	0.1416 mL	0.2832 mL	0.7080 mL
1M NaOH	100 mM	0.0227 mL	0.1133 mL	0.2266 mL	0.5664 mL

Folic acid Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Folic acid59-30-3Vitamin B9 Vitamin MVitamin B 9Vitamin B-9DNA/RNA SynthesisEnvironmental PollutantsEndogenous MetaboliteEnvironmental Contaminantsnutrientntidepressant-likeneural tube defectsfolic deficiencyInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Folic acid (Synonyms: Vitamin B9; Vitamin M)

Customer Review

Other Forms of Folic acid:

Folic acid Related Antibodies

25 Publications Citing Use of MCE Folic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All DNA/RNA Synthesis Isoform Specific Products:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Folic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Folic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report